The significant Q1 beat and positive pipeline updates (WVE-007 Phase 2a, WVE-006 data) are likely to drive the stock higher. Monitor the ATS conference in May for WVE-006 data and any regulatory feedback on accelerated approval.
Price Chart
Executive Summary
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), representing a massive beat. Net loss improved to $26.1M from $46.9M a year ago, and the company maintained a strong cash position of $544.6M. Pipeline catalysts include FDA acceptance of WVE-007 Phase 2a and upcoming AATD data.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $38.2M vs consensus $7.9M (beat by 384%)
- Q1 2026 EPS -$0.13 vs consensus -$0.31 (beat by 58%)
- Net loss improved to $26.1M from $46.9M YoY
- Cash and equivalents $544.6M, runway into Q3 2028
- FDA accepted Phase 2a multidose portion for WVE-007 (obesity), initiation on track for Q2 2026
- WVE-006 AATD data at ATS in May 2026; regulatory feedback on accelerated approval expected mid-2026
Financial Impact
Revenue beat of $30.3M vs consensus; EPS beat of $0.18; net loss improved by $20.8M YoY
Risk Factors
- Clinical trial delays or failures for WVE-007 and WVE-006
- Dilution from increased share count (200M vs 163M YoY)
- Still in net loss, though improving
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $5.41 $4.58 | ▼ −15.34% | ▼ −13.35% | $3.80 (−29.85%) |
May 18, 2026 19w ago | Press Release | $6.14 $5.95 | ▼ −3.09% | ▼ −4.08% | $3.80 (−38.19%) |
Apr 28, 2026 22w ago | 8-K | $7.52 $6.34 | ▼ −15.69% | ▼ −21.15% | $3.80 (−49.53%) |
Apr 28, 2026 22w ago | Press Release | $7.52 $6.38 | ▼ −15.16% | ▼ −20.63% | $3.80 (−49.53%) |
Apr 22, 2026 23w ago | Press Release | $7.38 $6.14 | ▼ −16.80% | ▼ −19.97% | $3.80 (−48.58%) |
Apr 15, 2026 24w ago | DEFA14A | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.80 (−48.16%) |
Apr 15, 2026 24w ago | 8-K | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.80 (−48.16%) |
Mar 26, 2026 27w ago | Press Release | $6.20 $7.18 | ▲ +15.81% | ▲ +5.14% | $3.80 (−38.79%) |
Feb 26, 2026 31w ago | 8-K | $15.36 $6.20 | ▼ −59.64% | ▼ −53.23% | $3.80 (−75.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access